According to GlaxoSmithKline's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.3322. At the end of 2022 the company had a P/E ratio of 4.14.
Year | P/E ratio | Change |
---|---|---|
2022 | 4.14 | -71.88% |
2021 | 14.7 | 45.85% |
2020 | 10.1 | -35.71% |
2019 | 15.7 | -0.75% |
2018 | 15.8 | -55.39% |
2017 | 35.5 | -44.04% |
2016 | 63.4 | 919.49% |
2015 | 6.22 | -66.06% |
2014 | 18.3 | 54.42% |
2013 | 11.9 | 0.16% |
2012 | 11.9 | 7.42% |
2011 | 11.0 | -64.77% |
2010 | 31.3 | 219.92% |
2009 | 9.79 | 6.19% |
2008 | 9.22 | -12.84% |
2007 | 10.6 | -11.42% |
2006 | 11.9 | -12.62% |
2005 | 13.7 | -10.16% |
2004 | 15.2 | 1.29% |
2003 | 15.0 | -17.25% |
2002 | 18.1 | -42.66% |
2001 | 31.7 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | 25.9 | 151.15% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 15.5 | 49.81% | ๐บ๐ธ USA |
![]() Sanofi SNY | 14.5 | 39.93% | ๐ซ๐ท France |
![]() Merck MRK | 58.0 | 461.21% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 32.0 | 210.05% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | -4.92 | -147.57% | ๐ฎ๐ฑ Israel |
![]() Dynavax Technologies
DVAX | 15.4 | 49.07% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.